Matinas BioPharma Provides Business Update and 2022 Strategic Outlook
January 25, 2022 06:30 ET
|
Matinas BioPharma Holdings, Inc.
– End of Phase 2 Meeting with FDA Provides Pathway to NDA Submission for MAT2203 Following Confirmatory Data to be Generated in an Additional Cohort; Cohort 5 in Ongoing EnACT Trial – – Cohort 4 of...
Matinas BioPharma to Provide Corporate Update and 2022 Business Outlook on January 25, 2022
January 18, 2022 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of...
Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
December 16, 2021 06:30 ET
|
Matinas BioPharma Holdings, Inc.
– DSMB evaluated both safety and efficacy data in recommending cohort progression – – Data from third patient cohort confirm antifungal activity above pre-defined threshold target for success, while...
Matinas BioPharma Appoints Thomas Hoover, M.B.A. as Chief Business Officer
December 06, 2021 06:30 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference
November 18, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
November 08, 2021 06:35 ET
|
Matinas BioPharma Holdings, Inc.
– Positive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously...
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial and Operational Results on November 8, 2021
November 02, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series
October 25, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
October 21, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
September 20, 2021 07:00 ET
|
Matinas BioPharma Holdings, Inc.
– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly – BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE...